MetrioPharm AG, a pharmaceutical development company, announces that the last patient was now examined during the currently ongoing clinical psoriasis Phase II study (Last Patient Last Visit).
The Phase II study was carried out in multiple clinical trial centers in Germany and Poland. A total of 154 patients with moderately-to-severe plaque-psoriasis were randomized. Patients received orally 150 mg or 300 mg of MP1032 or a placebo, twice a day.
The primary goal of the study is to evaluate clinical efficacy and safety of MP1032 in various dosages.
Dr. Petra Schulz, Senior Manager Drug Development: “After the last patient finalized the regular four week long follow-up period, we are confident, that MP1032 is proving its outstanding safety profile for the time period of the entire study.“
Dr. Wolfgang Brysch, CEO of MetrioPharm AG: “We are grateful to all the investigators, as well as all the patients, who made this study possible. The team at MetrioPharm is now awaiting the validation of the data. Afterwards we will immediately start the data analysis. We are expecting the study’s final results within the next few months.“